[Efficacy of dolutegravir in treatment-naïve patients. The SPRING-1, SPRING-2, SINGLE and FLAMINGO trials]
| Autor: | José I, Bernardino, Antonio, Antela |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Anti-HIV Agents Pyridones HIV Infections Middle Aged Piperazines Young Adult Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Antiretroviral Therapy Highly Active Oxazines HIV-1 Humans Multicenter Studies as Topic Drug Therapy Combination Female HIV Integrase Inhibitors Heterocyclic Compounds 3-Ring Aged Randomized Controlled Trials as Topic |
| Zdroj: | Enfermedades infecciosas y microbiologia clinica. 33 |
| ISSN: | 1578-1852 |
| Popis: | The efficacy of dolutegravir (DTG) in treatment-naïve patients has been analyzed in the SPRING 1 and 2, SINGLE and FLAMINGO trials, which compared dolutegravir with the agents currently recommended as the drugs of choice in clinical practice guidelines in treatment-naïve patients: efavirenz, raltegravir and darunavir/ritonavir. These trials confirmed the superiority (SINGLE and FLAMINGO) or the non-inferiority (SPRING-2) of dolutegravir. More than 2,000 patients were included in these 4 studies, lending value to their results and reinforcing the view of dolutegravir as the drug of choice in treatment-naïve patients, accompanied either by abacavir/lamivudine (Kivexa(®)) or tenofovir/emtricitabine (Truvada®). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|